Board of Directors

In a biopharma career spanning over thirty years, Anker Lundemose brings extensive international experience in areas of management (executive & board), business development, corporate development, M&A strategy, and execution, financing as well as R&D in key therapeutic areas including oncology, neuroscience, diabetes, obesity, CV/Kidney, immunology and anti-infectives. He is a serial entrepreneur and founder of several successful biotech companies, and has a broad international pharma, biotech and investor network. Several CEO positions over the years in both public as well as private companies and has worked in several different countries including DK, S, NL, N, UK, CH and the US. He is currently Chairman at Commit Biologics, Executive Chairman at Isomab Ltd., and Executive Director at Mission Therapeutics Ltd. Anker Lundemose has been involved in a total of six biotech exits/IPOs and has held Board positions in over 15 Biotech Companies since 2000.

In a biopharma and venture career spanning early‑stage therapeutics and company building, Dr. Philip Brainin brings 10+ years of clinical, scientific, and investment experience to his role as CEO of IsomAb. A physician‑scientist and MBA, he has a strong track record of translating cardiovascular and immunology science into value creation through disciplined portfolio construction, strategic partnering, and financing

Dr. Brainin previously served as a part of the investment teams at Sunstone Life Science Ventures and Sound Bioventures, where he defined the sourcing strategy and built a substantial biotech pipeline, converting multiple opportunities into investments across cardiovascular, renal, and rare diseases. He led cross‑functional due diligence and authored an impact framework for investors published in Nature Biotechnology.

He has advised Boards at BOOST Pharma, AnaCardio, NephroDI, VarmX (deal with CSL), and Arthex Biotech as well as the Therapeutics Advisory group at BioInnovation Institute. Dr. Brainin is an actively practising and qualified medical doctor with a PhD from the University of Copenhagen and an MBA from Copenhagen Business School, where he achieved the highest GPA in the history of the program. He has authored 40 peer-reviewed scientific publications and has been recognized with international scientific awards.

As a translational researcher for the last 32 years and Professor at Universities of Bristol, Nottingham and Pretoria, Prof Bates has spun out three companies based on his discoveries, and as Founding Director of the University of Nottingham Centre for Cancer Sciences from 2017 to 2023 has run strategic initiatives that cross multiple disciplines. David co-founded Exonate Ltd (2013), a Cambridge based clinical stage company developing anti-angiogenic eye drops where he was the Chief Scientific Officer until 2022. He has acted as a scientific advisor to major pharmaceutical companies including Pfizer, Takeda and Alcon. His academic research has contributed to the development of therapeutics in vascular eye disease and in cancer through collaborations with Roche and Astra Zeneca. He has published more than 200 papers and is the inventor on 13 patents.

ShiYin Foo is the scientific founder and CEO of Arvada Therapeutics. She is a cardiologist and immunologist with over 25 years of experience as a practicing physician and a catalyst in advancing innovative new programs through the various stages of drug development. She has been in executive and board roles at multiple biotechnology companies, including Cardioxyl Pharmaceuticals, Imara Therapeutics, Tiburio Therapeutics, Cydan II, and Thryv Therapeutics. ShiYin received her MD and PhD in Immunology from Stanford University, and a MMSc in Clinical Science from the Clinical Investigator Training Program at Harvard Medical School. She was clinical faculty at the Massachusetts General Hospital and Harvard Medical School, and a dual Diplomate of the American Board of Internal Medicine and in Cardiology.

Tom Needham, MBA, is a Managing Director at Broadview Ventures, leads the Biopharmaceuticals practice, and oversees Broadview’s investment strategy and venture portfolio management activities.

Tom also serves as Managing Director of Longview Ventures, an independent investment vehicle focused on clinical-stage opportunities, as a complement to Broadview’s dedication to Seed and Series A financings.

Tom has over 30 years of experience in venture capital investing, business development, corporate strategy, and C-suite executive management responsibilities in public and private biotechnology companies. Tom currently serves on the boards of IsomAb and Basking Biosciences, including serving as Basking’s Chairman (2020 thru 2023), as well as holds board observer roles at Comanche Bio, and Mosanna Therapeutics. Previously, Tom represented Broadview on the board at Antag Therapeutics, Renovacor (NYSE: RCOR, acquired by Rocket Pharma), including serving as Renovacor’s Chairman (2019 thru 2021), and held board observer roles at HAYA Therapeutics Alvereon Pharma, NIDO Surgical (acquired) and Cardero Therapeutics (now Epirium Bio).  Tom’s prior venture investment experience also includes working on Astex Pharmaceuticals (NASDAQ: ASTX, acquired by Otsuka), Enanta Pharmaceuticals (NASDAQ: ENTA), MD Everywhere (acquired by Marlin Equity Partners), Sirion Therapeutics (trade sale to Alcon and Bausch & Lomb) and Aegerion Pharmaceuticals (NASDAQ: AEGR).

Prior to joining Broadview Ventures, Tom was most recently Chief Business Officer at Merrimack Pharmaceuticals (NASDAQ: MACK) and Senior Vice President, Business Development at C4 Therapeutics (NASDAQ: CCCC). Previously, Tom spent 13 years as a healthcare and life sciences venture capital investor as Managing Director at Synthesis Capital, and as a Principal at the global private equity firm Advent International, as a member of the healthcare venture capital deal team in Boston. Earlier in his career, Tom held Vice President of Business Development positions at private and public biotech companies, where he led the negotiation and closing of a number of strategic transactions, including R&D partnerships with global pharmaceutical companies, licensing and M&A transactions. Tom holds a B.A. from Bowdoin College and an MBA from Babson College’s F.W. Olin Graduate School of Business.

Hannah Tapsell Chapman is an investor at Mercia Ventures, one of the UK’s most active venture capital firms. Bringing with her over a decade of experience working with early-stage companies, Hannah has a wealth of knowledge on how to commercialise innovations, scale up operations and raise capital. Hannah joined Mercia Ventures in 2022 and focuses on high-growth business in the Midlands. She serves as Investor Director on the board of several Mercia Ventures portfolio companies including Isomab, NuVision and Forge Genetics. Prior to joining Mercia, Hannah worked in a venture building team at the Ministry of Defence and in Capital Markets at the London Stock Exchange.

Laura is a Principal at SCVC, the official VC arm of Science Creates, where she invests in early-stage deep tech companies. She serves as Investor Director on the board of SCVC portfolio companies including Isomab and Bitrobius Genetics.

Laura has broad experience across the life sciences. She is a Biochemist with seven years research experience across industry and university settings, holding Masters and Doctoral degrees in Biochemistry from the University of Oxford. Her research experience includes three years at TCR T-cell therapy biotech Adaptimmune.

Prior to joining SCVC in 2021, Laura worked at BBSRC-UKRI developing funding programmes to support the commercialisation of academic research.

Paul is a familiar face in the UK biotech arena, having recently retired as the Chair of OBN UK Ltd (he remains a Board member), is the current Chair of Forge Genetics and has just stepped down as Executive Chair of IsomAb Ltd, having held the position for the past 4 years. Paul has over 40 years’ experience in the pharmaceutical and life science field; he has worked for Beecham Pharmaceuticals & Genzyme Corporation, where he headed the UK operations. In 2000, he became CEO of UK based biosimilars’ organisation, GeneMedix (GMX) plc and successfully led a dual listing on the London and Singapore Stock Exchanges. Paul has acted as a NED to Goldshield Group plc & BioProducts Laboratories and oversaw the sale of both organisations to Private Equity Groups. He acted as interim CEO to NanoMab Technology Ltd and served as the Chair of the UK BIA’s Manufacturing Advisory Committee. In 1998 he received the MBE for services to the biotechnology industry.